BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 10, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

New Zealand prepares major overhaul of drug, device regs

Jan. 15, 2019
By Tamra Sami
PERTH, Australia – After nearly 40 years, New Zealand is preparing new legislation to regulate drugs and devices that would replace the Medicines Act 1981.
Read More

Australia seeks industry feedback on aligning device definitions more closely with the EU

Jan. 14, 2019
By Tamra Sami

Australia proposes unique device identification system

Jan. 11, 2019
By Tamra Sami

Qiagen licenses Ellume's TB digital diagnostic, invests $15M

Jan. 10, 2019
By Tamra Sami

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Jan. 2, 2019
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Dec. 28, 2018
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Starpharma out-licenses Vivagel BV to ITF Pharma for U.S. market for $101M

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – In yet another regional carve-out deal for Starpharma Holdings Ltd., the company has out-licensed rights to its Vivagel BV for bacterial vaginosis (BV) to ITF Pharma for the U.S. market for roughly $101 million.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor. Brandon Capital Partners manages four life sciences funds with A$531 million (US$374.1 million) under management. Although it's the biggest venture fund in Australia, it's fairly small compared to some of its U.S. peers.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 9, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing